Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484145 | 0.90 | KMT2A (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19483595 | 0.89 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19484144 | 0.89 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17483145 | 0.89 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19484133 | 0.84 | KMT2A (0.38) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19484136 | 0.83 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19484139 | 0.81 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19484143 | 0.81 | NPC1 (0.32) | MEN1KMT2ANPC1RAB9ATRPV1 | |
| SCHEMBL19484151 | 0.80 | TRPV1 (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL17483129 | 0.79 | KMT2A (0.37) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | OPRM1, TRPA1, L3MBTL3 | MEN1 4192/4885KMT2A 1451/4885NPC1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.